CoChat

The role of C-reactive protein as an inflammatory marker in gastrointestinal diseases

Vermeire, Séverine, Van Assche, Gert, Rutgeerts, Paul · 2005 · Nature Clinical Practice Gastroenterology & Hepatology

The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.

Abstract

C-reactive protein (CRP) is an acute-phase protein that is produced in large amounts by hepatocytes, upon stimulation by the cytokines interleukin-6, tumor-necrosis-factor-alpha and interleukin-1beta, during an acute-phase response. CRP is an objective marker of inflammation and, in gastrointestinal diseases such as Crohn's disease and acute pancreatitis, its levels correlate well with clinical disease activity. In contrast to its use as a marker in Crohn's disease, however, CRP is a less reliable marker of inflammation and disease activity in patients with ulcerative colitis, except perhaps for severe, extensive colitis. The increased production of CRP after an acute-phase stimulus, such as active gut inflammation, might explain why strong anti-inflammatory agents, such as anti-tumor-necrosis-factor-alpha antibodies and other biologic agents, work particularly well in patients with increased levels of CRP. CRP is also useful as a laboratory marker to predict prognosis and relapse in patients with Crohn's disease and acute pancreatitis. Elevated CRP levels have been associated with an increased risk of colorectal cancer and are a marker of poor prognosis, indicating more advanced disease and, possibly, reduced survival. An important question that remains is how often CRP levels should be measured. Until there are more data, the use of CRP and of other biomarkers should be seen as an additional tool that aids clinical observation and physical examination, but that cannot repla…

Overview

Integrity signals

Registry

Crossref · 10.1038/ncpgasthep0359

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 1

  1. Rutgeerts P et al. (2003) Subanalysis from a phase 3 study on the evaluation of natalizumab in active Crohn's disease [Abstract]. Gut 52 (Suppl): A239

Cited by

See all 151

Metadata

Authors
Vermeire, S., Van Assche, G., & Rutgeerts, P.
Affiliations
Universitair Ziekenhuis Leuven (BE)
Corresponding author
Vermeire, Séverine
Venue
Nature Clinical Practice Gastroenterology & Hepatology
Published
2005-12
Volume
2
Issue
12
Pages
580-586
ISSN
  • 1743-4378 (ISSN-L)
  • 1743-4386
OpenAlex
W2036630215
Cited by
149
References
51
Citations by year
2026: 4 · 2025: 8 · 2024: 6 · 2023: 7 · 2022: 7 · 2021: 8 · 2020: 8 · 2019: 9 · 2018: 10 · 2017: 6 · 2016: 8 · 2015: 6 · 2014: 9 · 2013: 9 · 2012: 6
FWCI
0.79
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Nature Clinical Practice Gastroenterology & Hepatology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
  • Life Sciences › Immunology and Microbiology › Immunology › Biomarkers in Disease Mechanisms
  • Health Sciences › Medicine › Oncology › Inflammatory Biomarkers in Disease Prognosis
Keywords
C-reactive protein, inflammatory markers, gastrointestinal inflammation, Crohn's disease, ulcerative colitis, acute pancreatitis, disease activity monitoring, colorectal cancer risk, anti-TNF therapy, acute phase response, interleukin-6, TNF-α
MeSH terms
C-Reactive Protein, Gastrointestinal Diseases, Humans, Inflammation, Biomarkers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.